Abemaciclib D7
| Chemical Name | Abemaciclib D7 |
|---|---|
| Alternate Names | Abemaciclib Stable Isotopes, Stable Isotopes of Abemaciclib |
| CAT No. | CS-O-32772 |
| CAS Registry# | 1231929-97-7 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 513.64 g/mol |
| Mol. For. | C27H25D7F2N8 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Abemaciclib |
| Therapeutic | Anti-Cancer / Oncology |
| Canonical Smiles | CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F |
| InchIKey | UZWDCWONPYILKI-UHFFFAOYSA-N |
| Inchl | InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34) |
| IUPAC | N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Abemaciclib D7 is a deuterated version of Abemaciclib, which is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. It is used for the treatment of metastatic breast cancer that is hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-).
The chemical formula of Abemaciclib D7 is C27H32D7N8O2, and its molecular weight is 471.67 g/mol. The deuterated form of Abemaciclib has seven deuterium atoms substituted for hydrogen atoms, which makes it useful for pharmacokinetic and pharmacodynamic studies.
Abemaciclib D7 works by inhibiting the activity of CDK4 and CDK6 enzymes, which are involved in the regulation of the cell cycle. By blocking these enzymes, Abemaciclib D7 can slow down the growth and division of cancer cells, thereby reducing the size of tumors.
The recommended dosage of Abemaciclib D7 is 150 mg twice daily, with or without food. It is usually taken in combination with other medications such as aromatase inhibitors or fulvestrant. Common side effects of Abemaciclib D7 include fatigue, nausea, diarrhea, decreased appetite, and infections.
In conclusion, Abemaciclib D7 is a deuterated version of Abemaciclib that is used for the treatment of metastatic breast cancer. It works by inhibiting CDK4 and CDK6 enzymes, and its chemical structure makes it useful for pharmacokinetic and pharmacodynamic studies.
Get an Instant Quote
Related Compounds
Abemaciclib D10 | Abemaciclib D5 | Abemaciclib D8 | Abemaciclib Impurity 1 D12 | Abemaciclib Impurity 1 D5 | Abemaciclib Impurity 5 D5 |